Business Wire-logo

Business Wire

  • Business Wire
  • 101 California Street, 20th Floor
  • CA 94111 San Francisco
  • businesswire.com
Meddelelsestype
Vis

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release

Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t

Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release

AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe

SLB Announces Third-Quarter 2025 Results17.10.2025 12:50:00 CEST | Press release

Revenue of $8.93 billion increased 4% sequentially and decreased 3% year on year GAAP EPS of $0.50 decreased 32% sequentially and 40% year on year EPS, excluding charges and credits, of $0.69 decreased 7% sequentially and 22% year on year Net income attributable to SLB of $739 million decreased 27% sequentially and 38% year on year Adjusted EBITDA of $2.06 billion was flat sequentially and decreased 12% year on year Cash flow from operations was $1.68 billion and free cash flow was $1.10 billion, including $153 million of acquisition-related payments Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the third-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015948706/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2025Jun. 30, 2025Sept. 30, 2024Se

Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release

One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select

Bentley Systems Announces Winners of the 2025 Going Digital Awards17.10.2025 01:00:00 CEST | Press release

Company also recognizes key projects with Founders’ Honors, the Bentley-Envision winner for infrastructure sustainability, and the 2025 Bentley Educator of the Year (Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infr

Kinaxis Inc. to Host Third Quarter 2025 Financial Results Conference Call on November 6, 202516.10.2025 23:00:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its third quarter ended September 30, 2025. The call will be hosted on Thursday, November 6 at 8:30 a.m. Eastern Time by Bob Courteau, interim chief executive officer and chair, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the third quarter after the close of markets on Wednesday, November 5, 2025. CONFERENCE CALL DETAILSDATE: Thursday, November 6, 2025 TIME: 8:30 a.m. Eastern Time CALL REGISTRATION:https://registrations.events/direct/Q4I91416498WEBCAST:https://events.q4inc.com/attendee/875765587 (available for three months) Advance call registration Participants must register in advance for the live call. After registering, instructions on how to join the call will automatically be emailed, including dial-in informat

HCLTech and Zscaler Expand Partnership for AI-Powered Security and Network Transformation16.10.2025 20:13:00 CEST | Press release

HCLTech, a leading global technology company, and Zscaler™, a leader in cloud security, announced the expansion of their strategic partnership to provide AI-powered network transformation and enhanced zero-trust security services to enterprises worldwide. Under the new partnership scope, Zscaler's Zero Trust Exchange™ platform has been integrated with HCLTech's Cybersecurity Fusion Center (CSFC) platform. HCLTech’s AI capabilities, including SecOps and Responsible AI guardrails within HCLTech AI Force and AI Foundry are key to this partnership. This collaboration aims to enhance enterprise resilience and achieve business outcomes with a cloud-first, scalable security solution. HCLTech's Universal Managed Detection and Response (UMDR) services now integrate with Zscaler Internet Access™ (ZIA™), Zscaler Private Access™ (ZPA™) and other Zscaler components, providing context-rich threat detection, advanced analytics and faster response powered by AI and automation. Other key highlights of

Beyon Cyber and Haven Sign MoU to Launch Advanced AI-Powered SOC Capabilities in the UK and Worldwide16.10.2025 19:58:00 CEST | Press release

Beyon Cyber, part of the Beyon Group and the fastest growing cyber security company in the Middle East, has signed a Memorandum of Understanding (MoU) with Haven Cyber Technologies, a global cyber security services provider and a Microsoft Solutions Partner, through its UK-based subsidiary ITC Secure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016047852/en/ Beyon Cyber and Haven Sign MoU Under the MoU, Beyon Cyber and Haven will form a strategic partnership to revolutionize cyber security operations through the launch of advanced AI-driven Security Operations Centers (AI SOCs) in the United Kingdom and worldwide. As part of this collaboration, Haven will integrate Beyon Cyber’s cutting-edge AI SOC platform, Orryx AI, into its operations; harnessing the power of smart automation and agentic AI workflows to enhance threat detection, investigation, hunting, intelligence, and response. This partnership will enable both or

Stefanini Honored at ISG Women in Digital Awards EMEA as Natalia Chiritescu Wins Bronze Luminary for AI Leadership16.10.2025 17:23:00 CEST | Press release

Recognition underscores Stefanini’s AI-First strategy and global commitment to accelerating digital transformation through innovation and inclusion. Information Services Group (ISG) has honored Stefanini at the Women in Digital Awards in EMEA, celebrating Natalia Chiritescu. Chiritescu, Digital Solutions Center (DSC) Director for EMEA, NA, & APAC, was awarded “Bronze Luminary” in the AI Champion category recognizing AI adoption and enablement impact. The ISG Women in Digital Awards program, launched in the Americas in 2022, was expanded in 2023 to the Europe, Middle East and Africa (EMEA) and Asia Pacific regions, including India. In 2025, the global program had a total of 536 finalists and winners were announced on September. “The Women in Digital Awards aim to elevate and connect visionary women across the tech landscape. Natalia Chiritescu’s achievement is a testament to the program’s purpose: to foster collaboration, innovation, and diversity, empowering leaders to drive AI-enabled

CyberArk Named a Leader in the 2025 Gartner® Magic Quadrant™ for Privileged Access Management16.10.2025 17:06:00 CEST | Press release

CyberArk is recognized as a Leader for the seventh consecutive time.CyberArk's view is that recognition underscores the company's vision and innovation in the PAM market.CyberArk Identity Security Platform secures all identities with modern privilege controls. CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced it has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Privileged Access Management1. Recognized as a Leader for the seventh consecutive time, CyberArk is positioned furthest in Completeness of Vision which, from the company's standpoint, reflects CyberArk's commitment to defining the future of privilege access management (PAM), where every identity is protected with flexible as-needed access, smart AI-driven privilege controls, and unified security across both cloud and on-premises systems. The report evaluates tools that manage privileged access for both humans and machines. The CyberArk Identity Security Platform enables organizations

HistoSonics Announces Oversubscribed $250 Million Growth Financing16.10.2025 16:00:00 CEST | Press release

With backing from Peter Thiel, K5 Global, Jeff Bezos, and Wellington Management, among others, HistoSonics is positioned to expand globally across new clinical applications HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new ownership group and included additional investors Thiel Bio and Founders Fund, among others. The financing will support the ongoing commercial expansion of HistoSonics’ Edison System into new global markets, accelerate new clinical indications throughout the body, and strengthen operational capacity for the next phase of growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016119331/en/ HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics This funding follows the recent $2.25 billion majority stake acquisition of HistoSonics by a consor

The Estée Lauder Companies’ Oevel Manufacturing & Fulfillment Campus Celebrates 60 Years of Excellence and Innovation16.10.2025 15:01:00 CEST | Press release

The Estée Lauder Companies Inc. (NYSE:EL), today celebrated the sixtieth anniversary of its Manufacturing & Fulfillment Campus in Oevel, Belgium. Since its opening in 1965, the Oevel Campus has developed into a state-of-the-art manufacturing, fulfillment and biotech hub. Today the campus serves as a cornerstone of the company’s global value chain and is one of its largest manufacturing facilities by volume, annually producing over 100 million prestige beauty products, which are then shipped to more than 100 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016330616/en/ The Estée Lauder Companies celebrates 60th anniversary of its Manufacturing & Fulfillment Campus in Oevel, Belgium “Nearly sixty years ago, my grandparents, Estée and Joseph Lauder, laid the cornerstone of our first facility here in Oevel, establishing what would become a vital part of our global operations,” said William P. Lauder, Chair, Board of

Global Study Finds Most SAP Customers Favor Multi-Vendor Composable ERP for Faster Innovation, Including AI16.10.2025 15:00:00 CEST | Press release

Organizations using composable architectures with third-party support achieve above-average performance 83% of the time versus 27% for traditional approaches Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced research findings around the SAP roadmap. In an in-depth study and interactive interview of 455 IT and business leaders, SAP customers voiced concerns over the push toward subscription-based S/4HANA and shared strategies business leaders are adopting to drive innovation and growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016604661/en/ Global Study Finds Most SAP Customers Favor Multi-Vendor Composable ERP for Faster Innovation, Including AI Data revealed that while nearly all SAP customers surveyed are finding it difficult to

New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub16.10.2025 15:00:00 CEST | Press release

The Health & Pharma Solutions facility offers state-of-the-art laboratory and training rooms for customers Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, today, celebrates the grand opening of its dedicated Health & Pharma Solutions Innovation Center in São Paulo, Brazil. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016102423/en/ Credits to Roquette Located in Barueri, near São Paulo’s city center, the state-of-the-art facility represents a multi-million-dollar investment and reinforces Roquette’s commitment as the pharmaceutical industry’s go-to partner for the development of drug delivery solutions that contribute to life-saving therapies. The center will enable scientific experts to leverage advanced tools, technologies, and expertise to deliver tailored solutions to customers. “Roquette’s new Pharmaceutical Innovation Center in São
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
  • Business Wire
  • 101 California Street, 20th Floor
  • CA 94111 San Francisco
  • businesswire.com
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye